About us


Synspira is developing a new class of glycopolymer-based therapeutics that have the potential to address a major unmet need associated with pulmonary disorders- the chronic infection and related mucus accumulation and inflammation which often lead to exacerbations, hospitalizations and ultimately irreversible lung function decline in diseases including cystic fibrosis, chronic obstructive pulmonary disease (COPD), and pneumonia. Synspira is using proprietary modified polysaccharide molecules to disrupt cohesion of bacterial biofilms and thick mucus, exposing otherwise protected bacteria to antibiotics and potentiating the activity of traditional antibiotics. This new approach to the treatment of disease pathology has the potential to improve pulmonary function and reduce antibiotic resistance in a number of infectious diseases.